Treatment-related leukaemia—a clinical and scientific challenge
- 1 October 2000
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 26 (5) , 377-391
- https://doi.org/10.1053/ctrv.2000.0186
Abstract
No abstract availableKeywords
This publication has 92 references indexed in Scilit:
- Mutagenic damage to mammalian cells by therapeutic alkylating agentsPublished by Elsevier ,1999
- Phase II study of 21 day schedule oral etoposide in childrenEuropean Journal Of Cancer, 1997
- Translocation (3;21)(q26;q22) in therapy-related myelodysplasia following drugs targeting DNA-topoisomerase II combined with alkylating agnets, and in myeloproliferative disorders undergoing spontaneous leukemic transformationCancer Genetics and Cytogenetics, 1994
- DNA topoisomerase-trapping antitumour drugsEuropean Journal Of Cancer, 1992
- Implication of prior treatment with drug combinations including inhibitors of topoisomerase II in therapy-related monocytic leukemia with a 9;11 translocationGenes, Chromosomes and Cancer, 1990
- 11q23 abnormalities in children with acute nonlymphocytic leukemia (M4–M5)Cancer Genetics and Cytogenetics, 1990
- Leukemia Following Hodgkin's DiseaseNew England Journal of Medicine, 1990
- Secondary Acute Myeloid Leukemia in Children Treated for Acute Lymphoid LeukemiaNew England Journal of Medicine, 1989
- Risk of Second Cancers after Treatment for Hodgkin's DiseaseNew England Journal of Medicine, 1988
- Incidence of Acute Nonlymphocytic Leukemia, Preleukemia, and Acute Myeloproliferative Syndrome up to 10 Years after Treatment of Hodgkin's DiseaseNew England Journal of Medicine, 1982